跳至主要内容
临床试验/NCT02480751
NCT02480751已完成2 期

TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Toray Industries, Inc0 个研究点目标入组 113 人开始时间: 2005年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
113
主要终点
Difference between the run-in and treatment periods in the slope of the regression line of 1/SCr versus time

研究概览

简要总结

The purpose of this study is to determine the recommended dose of the sustained-release form of BPS (TRK-100STP low dose or high dose) in Japanese patients with CRF (Primary glomerular disease/nephrosclerosis).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 79 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The CRF patient with primary glomerular disease or nephrosclerosis as the primary disease
  • The patient with progressive CRF

排除标准

  • The patient with secondary glomerular disease
  • The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty kidney, polycystic kidney disease, or nephroureterolithiasis

研究组 & 干预措施

1: Exprimental (TRK-100STP)

Experimental

high dose

干预措施: Beraprost (Drug)

2: Exprimental (TRK-100STP)

Experimental

low dose

干预措施: Beraprost (Drug)

3: Placebo Comparator

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Difference between the run-in and treatment periods in the slope of the regression line of 1/SCr versus time

时间窗: 50 weeks (Run-in 22weeks, Treatment 28 weeks)

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验